Dedicated cohort for mCRPC with CDK12 alterations, which has aggressive clinical behavior https://t.co/lzaKvKAf1p and may respond to CPI https://t.co/pNb35gYgO5 https://t.co/mhTfqsnOmE https://t.co/NCVYz8qKnt
RT @EricTopol: Discovery of a new type of prostate #cancer in ~7% of patients, w/ biomarker, more responsive to immune checkpoint Rx https://t.co/cPbSNIjp6d @CellCellPress @CellPressNews impact of CDK12 @umichmedicine @UMRogelCancer https://t.co/BqWVP4PmTF
@DanLinMD @mishabeltran @fredhutch @SeattleCCA Identifying genomic subsets increasingly important beyond just "targeted therapy". Finding CDK12 or MSI opens up #immunotherapy possibilities for #prostatecancer. Need more research linking genomics to immune
CDK12 mutations in prostate cancer seem to confer benefit in a subset of prostate cancer patients https://t.co/7IdNxxTkuN #PrecisionMedicine #Prostatecancer #Genomics
Inactivation of CDK12 delineates a distinct immunogenic class of advanced prostate cancer https://t.co/kJDiXviD4V
RT @DaleYuzuki: De Bono #AACR19 Shows fig from '18 Cell https://t.co/kig8IjorbL
RT @DaleYuzuki: De Bono #AACR19 Shows fig from '18 Cell https://t.co/kig8IjorbL
De Bono #AACR19 Shows fig from '18 Cell https://t.co/kig8IjorbL
Eric Topol: Discovery of a new type of prostate #cancer in ~7% of patients, w/ biomarker, more responsive to immune checkpoint Rx https://t.co/QuCMhFFew4 @CellCellPress @CellPressNews impact of CDK12 @umichmedicine @UMRogelCancer https://t.co/O8KiNspJWD #m
The paper was published in June in @CellCellPress: 'Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer' https://t.co/znl0bYvRc3
RT @Yegnalab: A series of excellent studies surveying structural alterations in metastatic prostate cancer and association with specific mu…
A series of excellent studies surveying structural alterations in metastatic prostate cancer and association with specific mutations: https://t.co/vAqGsXR1vo, https://t.co/rSOGyYUnlk, https://t.co/52CsDanuKi.
RT @Dr_RaviMadan: Can #CDK12 loss identify a subset (~7%) of mCRPC pts with #immunotherapy responsive tumors? Provocative study from #PCF…
RT @Dr_RaviMadan: Can #CDK12 loss identify a subset (~7%) of mCRPC pts with #immunotherapy responsive tumors? Provocative study from #PCF…
RT @Dr_RaviMadan: Can #CDK12 loss identify a subset (~7%) of mCRPC pts with #immunotherapy responsive tumors? Provocative study from #PCF…
Can #CDK12 loss identify a subset (~7%) of mCRPC pts with #immunotherapy responsive tumors? Provocative study from #PCF #SU2C International #ProstateCancer Dream Team article via: https://t.co/LKY2OkiaQH @CellCellPress https://t.co/XFR3IMBL6F
RT @mmw_lmw: An Immunogenic Class of #ProstateCancer | CDK12 Inactive | May benefit from #CheckPoint Blockade | Arul Chinnaiyan @UMich @Cel…
RT @mmw_lmw: An Immunogenic Class of #ProstateCancer | CDK12 Inactive | May benefit from #CheckPoint Blockade | Arul Chinnaiyan @UMich @Cel…
RT @mmw_lmw: An Immunogenic Class of #ProstateCancer | CDK12 Inactive | May benefit from #CheckPoint Blockade | Arul Chinnaiyan @UMich @Cel…
RT @mmw_lmw: An Immunogenic Class of #ProstateCancer | CDK12 Inactive | May benefit from #CheckPoint Blockade | Arul Chinnaiyan @UMich @Cel…
RT @mmw_lmw: An Immunogenic Class of #ProstateCancer | CDK12 Inactive | May benefit from #CheckPoint Blockade | Arul Chinnaiyan @UMich @Cel…
RT @mmw_lmw: An Immunogenic Class of #ProstateCancer | CDK12 Inactive | May benefit from #CheckPoint Blockade | Arul Chinnaiyan @UMich @Cel…
RT @mmw_lmw: An Immunogenic Class of #ProstateCancer | CDK12 Inactive | May benefit from #CheckPoint Blockade | Arul Chinnaiyan @UMich @Cel…
RT @mmw_lmw: An Immunogenic Class of #ProstateCancer | CDK12 Inactive | May benefit from #CheckPoint Blockade | Arul Chinnaiyan @UMich @Cel…
An Immunogenic Class of #ProstateCancer | CDK12 Inactive | May benefit from #CheckPoint Blockade | Arul Chinnaiyan @UMich @CellCellPress https://t.co/IpGyVQtTdF | #JuneReCap https://t.co/j4A1WB2SNc
RT @CellCellPress: Now at Cell: Wu et al. identify a subtype of metastatic (castration-resistant) #Prostate #Cancer potentially targetable…
RT @gulleyj1: Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer #PCFAcademy https://t.co/83NGA9Ucny
RT @CellCellPress: Now at Cell: Wu et al. identify a subtype of metastatic (castration-resistant) #Prostate #Cancer potentially targetable…
RT @CellCellPress: Now at Cell: Wu et al. identify a subtype of metastatic (castration-resistant) #Prostate #Cancer potentially targetable…
RT @CellCellPress: Now at Cell: Wu et al. identify a subtype of metastatic (castration-resistant) #Prostate #Cancer potentially targetable…
RT @CellCellPress: Now at Cell: Wu et al. identify a subtype of metastatic (castration-resistant) #Prostate #Cancer potentially targetable…
RT @CellCellPress: Now at Cell: Wu et al. identify a subtype of metastatic (castration-resistant) #Prostate #Cancer potentially targetable…
RT @CellCellPress: Now at Cell: Wu et al. identify a subtype of metastatic (castration-resistant) #Prostate #Cancer potentially targetable…
RT @CellCellPress: Now at Cell: Wu et al. identify a subtype of metastatic (castration-resistant) #Prostate #Cancer potentially targetable…
RT @CellCellPress: Now at Cell: Wu et al. identify a subtype of metastatic (castration-resistant) #Prostate #Cancer potentially targetable…
RT Now at Cell: Wu et al. identify a subtype of metastatic (castration-resistant) #Prostate #Cancer potentially targetable with #ImmuneCheckpoint inhibitors https://t.co/JhJWvofIgX https://t.co/Xll8PxcNaU
Now at Cell: Wu et al. identify a subtype of metastatic (castration-resistant) #Prostate #Cancer potentially targetable with #ImmuneCheckpoint inhibitors https://t.co/ne9BOGG818 https://t.co/BGmbM1aoum
RT @gulleyj1: Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer #PCFAcademy https://t.co/83NGA9Ucny
RT @gulleyj1: Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer #PCFAcademy https://t.co/83NGA9Ucny
RT @gulleyj1: Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer #PCFAcademy https://t.co/83NGA9Ucny
RT @gulleyj1: Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer #PCFAcademy https://t.co/83NGA9Ucny
RT @gulleyj1: Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer #PCFAcademy https://t.co/83NGA9Ucny
RT @gulleyj1: Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer #PCFAcademy https://t.co/83NGA9Ucny
RT @gulleyj1: Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer #PCFAcademy https://t.co/83NGA9Ucny
RT @gulleyj1: Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer #PCFAcademy https://t.co/83NGA9Ucny
RT @gulleyj1: Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer #PCFAcademy https://t.co/83NGA9Ucny
RT @gulleyj1: Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer #PCFAcademy https://t.co/83NGA9Ucny
Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer #PCFAcademy https://t.co/83NGA9Ucny
RT @PCF_Science: THREE #PCFfunded studies published in @CellCellPress @CellPressNews today! We are so proud to have supported these #prost…
RT @MIgnatiadis: Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer: Cell https://t.co/0C594KWvpT
Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer: Cell https://t.co/0C594KWvpT
RT @EricTopol: Discovery of a new type of prostate #cancer in ~7% of patients, w/ biomarker, more responsive to immune checkpoint Rx https:…
RT @EricTopol: Discovery of a new type of prostate #cancer in ~7% of patients, w/ biomarker, more responsive to immune checkpoint Rx https:…
#CDK12不活化 PCは免疫感受性サブセット。チェックポイントブロッカーの高度適応であることを示唆:University of Michigan, https://t.co/QmmRwY3q5P
Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced #ProstateCancer @CellCellPress @UMich @fredhutch @UCSF https://t.co/GGRpyL1Okx https://t.co/6xM00xvpLv
RT @EricTopol: Discovery of a new type of prostate #cancer in ~7% of patients, w/ biomarker, more responsive to immune checkpoint Rx https:…
RT @dr_khaledamiri: اكتشاف نوع جديد من سرطان البروستات بخصائص بصمات جينية مختلفة وتم التعرف عليها بواسطة دراسة جينومية مكثفة....👈🏻 https://…
RT @EricTopol: Discovery of a new type of prostate #cancer in ~7% of patients, w/ biomarker, more responsive to immune checkpoint Rx https:…
RT @EricTopol: Discovery of a new type of prostate #cancer in ~7% of patients, w/ biomarker, more responsive to immune checkpoint Rx https:…
RT @mmw_lmw: An Immunogenic Class of #ProstateCancer | CDK12 Inactive | May benefit from #CheckPoint Blockade | Arul Chinnaiyan @UMich @Cel…
RT @EricTopol: Discovery of a new type of prostate #cancer in ~7% of patients, w/ biomarker, more responsive to immune checkpoint Rx https:…
RT @mmw_lmw: An Immunogenic Class of #ProstateCancer | CDK12 Inactive | May benefit from #CheckPoint Blockade | Arul Chinnaiyan @UMich @Cel…
RT @mmw_lmw: An Immunogenic Class of #ProstateCancer | CDK12 Inactive | May benefit from #CheckPoint Blockade | Arul Chinnaiyan @UMich @Cel…
RT @mmw_lmw: An Immunogenic Class of #ProstateCancer | CDK12 Inactive | May benefit from #CheckPoint Blockade | Arul Chinnaiyan @UMich @Cel…
An Immunogenic Class of #ProstateCancer | CDK12 Inactive | May benefit from #CheckPoint Blockade | Arul Chinnaiyan @UMich @CellCellPress https://t.co/IpGyVQtTdF https://t.co/vsX5l50mtL
RT @mmw_lmw: An Immunogenic Class of #ProstateCancer | CDK12 Inactive | May benefit from #CheckPoint Blockade | Arul Chinnaiyan @UMich @Cel…
RT @mmw_lmw: An Immunogenic Class of #ProstateCancer | CDK12 Inactive | May benefit from #CheckPoint Blockade | Arul Chinnaiyan @UMich @Cel…
RT @mmw_lmw: An Immunogenic Class of #ProstateCancer | CDK12 Inactive | May benefit from #CheckPoint Blockade | Arul Chinnaiyan @UMich @Cel…
RT @mmw_lmw: An Immunogenic Class of #ProstateCancer | CDK12 Inactive | May benefit from #CheckPoint Blockade | Arul Chinnaiyan @UMich @Cel…
An Immunogenic Class of #ProstateCancer | CDK12 Inactive | May benefit from #CheckPoint Blockade | Arul Chinnaiyan @UMich @CellCellPress https://t.co/IpGyVQtTdF https://t.co/ECTI4QwuhE
RT @EricTopol: Discovery of a new type of prostate #cancer in ~7% of patients, w/ biomarker, more responsive to immune checkpoint Rx https:…
RT @mmw_lmw: An Immunogenic Class of #ProstateCancer | CDK12 Inactive | May benefit from #CheckPoint Blockade | Arul Chinnaiyan @UMich @Cel…
RT @VasanthiViswa: Congratulations @srviswanathan (a.k.a hubs) and @GavinHa. Can't believe that AR enhancer (amplified in over 75% of castr…
RT @mmw_lmw: An Immunogenic Class of #ProstateCancer | CDK12 Inactive | May benefit from #CheckPoint Blockade | Arul Chinnaiyan @UMich @Cel…
RT @mmw_lmw: An Immunogenic Class of #ProstateCancer | CDK12 Inactive | May benefit from #CheckPoint Blockade | Arul Chinnaiyan @UMich @Cel…
RT @PCF_Science: 1-- #PCFfunded study published in @CellCellPress @CellPressNews today identifies CDK12-loss as biomarker of distinct new #…
A tour de force! I never cease to be amazed by the clever manifestations genetic adaptions due to selective pressure from bottleneck events within cancer patients. I'm excited to see how these studies shape drug development. #pcsm https://t.co/lxtAtOtBKL
RT @EricTopol: Discovery of a new type of prostate #cancer in ~7% of patients, w/ biomarker, more responsive to immune checkpoint Rx https:…
RT @PCF_Science: THREE #PCFfunded studies published in @CellCellPress @CellPressNews today! We are so proud to have supported these #prost…
RT @EricTopol: Discovery of a new type of prostate #cancer in ~7% of patients, w/ biomarker, more responsive to immune checkpoint Rx https:…
RT @PCF_Science: 1-- #PCFfunded study published in @CellCellPress @CellPressNews today identifies CDK12-loss as biomarker of distinct new #…
RT @PCF_Science: 1-- #PCFfunded study published in @CellCellPress @CellPressNews today identifies CDK12-loss as biomarker of distinct new #…
RT @EricTopol: Discovery of a new type of prostate #cancer in ~7% of patients, w/ biomarker, more responsive to immune checkpoint Rx https:…
RT @mmw_lmw: An Immunogenic Class of #ProstateCancer | CDK12 Inactive | May benefit from #CheckPoint Blockade | Arul Chinnaiyan @UMich @Cel…
RT @EricTopol: Discovery of a new type of prostate #cancer in ~7% of patients, w/ biomarker, more responsive to immune checkpoint Rx https:…
RT @mmw_lmw: An Immunogenic Class of #ProstateCancer | CDK12 Inactive | May benefit from #CheckPoint Blockade | Arul Chinnaiyan @UMich @Cel…
RT @mmw_lmw: An Immunogenic Class of #ProstateCancer | CDK12 Inactive | May benefit from #CheckPoint Blockade | Arul Chinnaiyan @UMich @Cel…
RT @mmw_lmw: An Immunogenic Class of #ProstateCancer | CDK12 Inactive | May benefit from #CheckPoint Blockade | Arul Chinnaiyan @UMich @Cel…
RT @mmw_lmw: An Immunogenic Class of #ProstateCancer | CDK12 Inactive | May benefit from #CheckPoint Blockade | Arul Chinnaiyan @UMich @Cel…
An Immunogenic Class of #ProstateCancer | CDK12 Inactive | May benefit from #CheckPoint Blockade | Arul Chinnaiyan @UMich @CellCellPress https://t.co/IpGyVQtTdF https://t.co/V1dW9Zj9vM
RT @pknoepfler: A new type of prostate cancer https://t.co/K1RHdAfjw4
RT @EricTopol: Discovery of a new type of prostate #cancer in ~7% of patients, w/ biomarker, more responsive to immune checkpoint Rx https:…
RT @jake_kloeber: Interesting work identifying a new class of prostate cancer characterized by inactivation of CDK12, focal tandem duplicat…
RT @DocDellaire: Newly identified CDK12 subtype of prostate cancer that responds to immune checkpoint therapy! @AminaZoubeidi https://t.co/…
RT @EricTopol: Discovery of a new type of prostate #cancer in ~7% of patients, w/ biomarker, more responsive to immune checkpoint Rx https:…